Since, as things stand, Ursula von der Leyen will only be elected if she can gather a majority behind her in the EU Parliament, she is dependent on alliances. The fact that during a recent panel discussion she reached out to parties that, like the right-wing conservative EKR group, are to the right of the EPP, brought her a lot of criticism. At the CDU party conference, she therefore saw the need to make it clear once again that cooperation can only take place with parties that meet three requirements: “A clear commitment to the rule of law, a clear commitment to Ukraine and against the crimes of the Kremlin and a clear commitment to Europe”.
Related
The Cinépolis promotion that you can apply if you are going to vote on June 2
Cinepolis wants you to be a responsible citizen and vote on June 2so if you do, you can apply for the super promotion that the movie theater chain has for you.
The chain of theaters Cinepolis It joins the promotions for all responsible citizens who are going to vote this June 2.
Promotion that you can easily apply in Cinepolis and it has several benefits for you; so pay attention to take advantage of it.
This is the promotion that you can apply at Cinépolis if you are going to vote on June 2
To encourage citizens, Cinepolis has a promotion for all those citizens responsible for going to vote on June 2.
Hence If you are going to vote on June 2 You can apply for Cinépolis promotions which will be:
- 4 tickets for a price of 100 pesos for traditional Cinépolis, Cinépolis Plus, Macro XE and Cinépolis Junior screenings
- 4 tickets with a price of 200 pesos for Cinépolis VIP, IMAX, 4DX and ScreenX screenings
- Free basket of small size butter flavored popcorn
This you must do to get the Cinépolis promotion if you are going to vote on June 2
It will be very easy to obtain the Cinépolis promotion that you can apply if you are going to vote on June 2.
Most read in Business
Since the most important thing about this will be to be a responsible citizen and go to vote in your polling station this coming June 2 andn presidential and local elections.
After this you must go to your Cinepolis favorite show your marked finger that proves that you voted and your INE at the box office to get the promotion of 4 tickets for 100 or 200 pesos depending on your preference.
While to have the promotion of a basket of free small-size butter-flavored popcorn at Cinépolis you will have to Present your proof of ticket purchase, your marked finger and INE at the candy store.
And that’s it, so you will not only be a responsible citizen by going to vote this June 2, but you will also be able to have fun going to the movies with Cinepolis.
The Cinépolis promotion that you can apply if you are going to vote on June 2
SK Biopharm Surpasses Expectations with First Quarter Surplus and Plans for Second Commercial Product Launch
SK Biopharm gets green light for annual surplus… “We will get the second commercial product soon. “
[이데일리 김진수 기자] SK Biopharm announced its performance in the first quarter of this year and announced on the 9th that it achieved a surplus in operating profit in the first quarter due to rapid growth in sales of cenobamate (US product name : Xcopri).
SK Biopharm’s first quarter sales were KRW 114 billion and operating profit was KRW 10.3 billion, exceeding market consensus for both sales and operating profit. SK Biopharm recorded an 87.5% increase in sales compared to the same period last year through increased sales of cenobamate and several other sales. In particular, considering the size of the US sales of Cenobamate, which has grown to about 90 billion won, it is analyzed that an additional stable structure has been secured.
Other sales are also expected to be strong in general, reaching 23.1 billion won in the quarter, exceeding the annual guidance of 70 billion won at the beginning of the year.
SK Biopharmaceuticals achieved a surplus for two consecutive quarters for the first time since its establishment, and it is significant that the surplus was achieved in the first quarter entirely due to growth in sales of cenobamate in the US. Therefore, the goal of achieving an annual surplus is expected to be on track.
Cenobamate’s US sales in the first quarter amounted to KRW 90.9 billion, showing rapid growth of 68.5% compared to the same period last year and 17% compared to the previous quarter. Considering the sales volume and gross profit ratio of 90%, it is expected that the company will be able to achieve a stable surplus in the future.
In terms of other sales, sales from various sources of income show a good performance, such as sales of semi-finished product DP / API in the first quarter, royalty income from cenobamate Europe and solriamfetol, sales from clinical trials in Asia, and other service sales. As a result, there is another sales guide at the beginning of the year 700. It is expected that it will exceed 100 million won.
In the first quarter of this year, cenobamate continued to grow rapidly by maintaining a high number of new patient prescriptions (NBRx) in the US market. The total number of monthly prescriptions for cenobamate in March, 47 months after its launch, was about 27,000, which is about 2.3 times the number of prescriptions for a competing new drug 47 months after its launch soft SK Biopharmaceuticals aims to grow faster this year by increasing the number of monthly prescriptions (TRx) through new education and marketing programs and better incentives, thereby achieving the No. 1 position in drug prescriptions in the ‘TA’ (Therapeutic Area).
SK Biopharmaceuticals is preparing for a quantum leap in sales by expanding the indications for cenobamate to general seizures and expanding the age range to include children and adolescents by 2026.
Construction of the second commercial product and industrial material TPD and RPT
Along with the growth of Cenobamate, SK Biopharmaceuticals is growing at an accelerated rate by introducing external commercial products that utilize the existing marketing infrastructure, and based on the funds in addition that comes from here, the company is developing a new modality and anti-technology platform. – cancer technology The plan is to expand the field and make full-scale progress towards becoming a ‘big biotech’.
SK Biopharmaceuticals is the only Korean biopharmaceutical company that has a direct sales system and sells its own innovative drugs in the US market. Cenobamate operates through a direct sales system, ensuring high profitability with a gross profit ratio in the mid-90s in the US, and SK Biopharmaceuticals plans to introduce a ‘second commercial product’ that will fully need for US direct sales infrastructure. .
SK Biopharm selected RPT (Radiopharmaceutical Therapeutics), TPD (Targeted Protein Degradation Therapeutics), and CGT (Cell Gene Therapy) as the three new methods through a new financial story last year, and based on cooperation with SK Group, we are ‘ accelerate R&D in all areas.
In the TPD area, we successfully acquired SK Life Science Labs last year and are ‘best in class’ to work on previously untreated targets through ‘MOPED’, an innovative platform for to find molecular glue (MG). sourcing and developing best-in-class and first-rate linemen, and plans to present an integrated pipeline and development schedule within the year.
In the field of RPT, the plan is to announce a business plan, including a detailed strategic direction and schedule of the RPT business, including the acquisition of stable radioisotopes (RI), to lead the RPT business as a first mover in the Asian region.
2024-05-09 02:25:24
#Biopharm #green #light #annual #surplus.. #commercial #product
Related posts: